risperidone has been researched along with Dyskinesia, Medication-Induced in 196 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was to evaluate the effects on clinical symptoms and cognitive function of switching the treatment of elderly patients with schizophrenia from risperidone to paliperidone (PAL)." | 9.19 | The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. ( Gen, K; Hibino, H; Inoue, Y; Matsumoto, H; Mikami, A; Mikami, K; Suzuki, H, 2014) |
| "In this multicenter, phase 3, randomized, double-blind, parallel-group study, only patients with DSM-IV schizophrenia who had failed an adequate antipsychotic treatment within the previous 6 months and who had not responded positively to haloperidol during screening were eligible for enrollment." | 9.15 | A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. ( Buckley, PF; Daniel, DG; Kane, JM; Potkin, SG, 2011) |
| "This open-label, rater-blinded, parallel-group study was designed to evaluate noninferiority of paliperidone palmitate (PP), a once-monthly injectable atypical antipsychotic, to once-biweekly risperidone long-acting injectable (RIS-LAI) in adult Chinese patients with acute schizophrenia." | 9.15 | A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. ( Gu, N; Li, H; Ning, X; Rui, Q; Xu, H, 2011) |
| "The aim of this study was to evaluate the efficacy and safety of two dose ranges of risperidone in adolescents with schizophrenia." | 9.14 | A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. ( Armenteros, J; Copenhaver, MD; Haas, M; Kushner, SF; Quiroz, JA; Unis, AS, 2009) |
| "The current study evaluated the efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia." | 9.13 | Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. ( Casey, DE; Heisterberg, J; Sands, EE; Yang, HM, 2008) |
| "This open-label, multicentre study investigated the clinical efficacy of liquid peroral risperidone in psychotic disorders, the patients' attitudes toward the study medication vs." | 9.11 | Risperidone liquid in psychotic disorders--efficacy and attitudes. ( Damjanović, A; Jasović-Gasić, M; Marić, N, 2005) |
| "The efficacy and safety of risperidone long-acting injectable (RLAI) was investigated in patients in the early phases of schizophrenia and schizoaffective disorders (< or = 3 years)." | 9.11 | Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. ( Andrezina, R; Gaebel, W; Glue, P; Masiak, M; Medori, R; Milanova, V; Parellada, E; Turner, MS, 2005) |
| "The long-term safety and efficacy of long-acting injectable risperidone, the first long-acting second-generation antipsychotic, were evaluated in stable patients with schizophrenia." | 9.10 | Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. ( Chrzanowski, W; Eerdekens, M; Fleischhacker, WW; Gefvert, O; Karcher, K; Llorca, PM; Martin, S; Remington, G, 2003) |
| "Atypical neuroleptics, including risperidone, are used to treat children with autism, despite limited efficacy and safety data." | 9.10 | Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. ( Choudhury, MS; Delaney, MA; Gifford, C; Maislin, G; Malone, RP, 2002) |
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 9.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| "A double-blind, placebo-controlled trial was performed to determine the efficacy and tolerability of 8 weeks of treatment with risperidone in the management of 48 adolescent and adult patients with Tourette syndrome." | 9.10 | Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial. ( Annable, L; Chouinard, G; Dion, Y; Sandor, P, 2002) |
| "Data on risperidone's efficacy and tolerability in adolescents with schizophrenia are scarce." | 9.10 | Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. ( Bensason, D; Carmon, E; Martin, A; Tyano, S; Weizman, A; Zalsman, G, 2003) |
| "The authors studied the incidence of tardive dyskinesia in elderly institutionalized patients with dementia being treated with risperidone." | 9.09 | Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. ( Jeste, DV; Kane, JM; Martinez, RA; Napolitano, J; Okamoto, A, 2000) |
| "The purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with treatment-refractory schizophrenia." | 9.09 | Risperidone in treatment-refractory schizophrenia. ( Green, MF; Marder, SR; Marshall, BD; Mintz, J; Wirshing, DA; Wirshing, WC, 1999) |
| "The efficacy and safety of risperidone have previously been demonstrated in controlled clinical trials in hospitalized chronic schizophrenia patients who met strict research criteria." | 9.08 | A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial. ARCS Study Group. Assessment of Risperdal in a Clinical Setting. ( Brecher, M; Clyde, C; Jeste, DV; Jones, R; Klausner, M, 1997) |
| " We aimed to establish the dose-response relationship for oral risperidone in relapsed schizophrenia." | 8.83 | Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. ( Ezewuzie, N; Taylor, D, 2006) |
| "Risperidone offers physicians the unique combination of extensive, published clinical experience and a good safety profile for treating patients with dementia who have symptoms of aggression, agitation, and psychosis." | 8.81 | Risperidone for the treatment of behavioral and psychological symptoms of dementia. ( Tune, LE, 2001) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 7.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "An open-label, multicentre study was conducted to assess the long-term efficacy and safety of risperidone in patients with chronic schizophrenia." | 7.70 | Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. ( Addington, DE; Gagiano, CA; Gaussares, C; Möller, HJ; Torres-Plank, JF; Von Knorring, L, 1998) |
| "Risperidone was hypothesized to have better extrapyramidal tolerability and efficacy in treating negative symptoms." | 6.73 | Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. ( Braus, DF; Buchkremer, G; Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klosterkötter, J; Kühn, KU; Maier, W; Möller, HJ; Ohmann, C; Riedel, M; Riesbeck, M; Schlösser, R; Schneider, F; Wickelmaier, F, 2008) |
| "Domperidone is a dopamine D₂ receptor antagonist that does not usually cross the blood-brain barrier." | 5.37 | Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia. ( Bocti, C; Hottin, P; Landry, J; Roy-Desruisseaux, J; Tessier, D; Trudel, JF, 2011) |
| "Haloperidol patients were more often single and institutionalised, less educated, had more residual schizophrenia, were longer hospitalised in the previous year, took more corrective and psychotropic drugs and had more extrapyramidal symptoms (EPS) and gynaecomastia (all significantly)." | 5.35 | Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. ( Albert, A; De Graeve, D; Gillain, B; Peuskens, J; Van Vleymen, B, 2009) |
| " Failure in switching to monotherapy was associated with higher dosage of antipsychotics at baseline." | 5.33 | Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia. ( Kunugi, H; Murray, RM; Nakanishi, S; Nojima, S; Ogawa, T; Takahashi, T, 2006) |
| "This study was to evaluate the effects on clinical symptoms and cognitive function of switching the treatment of elderly patients with schizophrenia from risperidone to paliperidone (PAL)." | 5.19 | The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. ( Gen, K; Hibino, H; Inoue, Y; Matsumoto, H; Mikami, A; Mikami, K; Suzuki, H, 2014) |
| "Subjects with schizophrenia age 50 years or more who were clinically stable and previously maintained on oral risperidone for D(2/3) RRO in dorsal putamen was assessed, using the region of interest analysis of [¹¹C]raclopride PET scans, before and after the dose reduction." | 5.19 | Therapeutic window for striatal dopamine D(2/3) receptor occupancy in older patients with schizophrenia: a pilot PET study. ( Arenovich, T; Graff-Guerrero, A; Mamo, DC; Mulsant, BH; Pollock, BG; Rajji, TK; Suzuki, T; Uchida, H, 2014) |
| "In this multicenter, phase 3, randomized, double-blind, parallel-group study, only patients with DSM-IV schizophrenia who had failed an adequate antipsychotic treatment within the previous 6 months and who had not responded positively to haloperidol during screening were eligible for enrollment." | 5.15 | A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. ( Buckley, PF; Daniel, DG; Kane, JM; Potkin, SG, 2011) |
| "This open-label, rater-blinded, parallel-group study was designed to evaluate noninferiority of paliperidone palmitate (PP), a once-monthly injectable atypical antipsychotic, to once-biweekly risperidone long-acting injectable (RIS-LAI) in adult Chinese patients with acute schizophrenia." | 5.15 | A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. ( Gu, N; Li, H; Ning, X; Rui, Q; Xu, H, 2011) |
| "The aim of this study was to evaluate the efficacy and safety of two dose ranges of risperidone in adolescents with schizophrenia." | 5.14 | A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. ( Armenteros, J; Copenhaver, MD; Haas, M; Kushner, SF; Quiroz, JA; Unis, AS, 2009) |
| " Sixty patients with DSM-IV schizophrenia (n = 58) or schizoaffective disorder (n = 2) met the DSM-IV research criteria for neuroleptic-induced tardive dyskinesia and were randomly assigned to a risperidone or olanzapine group." | 5.14 | A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. ( Chan, HY; Chang, CJ; Chen, CH; Chen, JJ; Chiang, SC; Gau, SS; Hwu, HG; Lai, MS, 2010) |
| "The current study evaluated the efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia." | 5.13 | Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. ( Casey, DE; Heisterberg, J; Sands, EE; Yang, HM, 2008) |
| "The aim of the study was to compare safety, efficacy and tolerability of risperidone with haloperidol in the treatment of Autistic Disorder (AD)." | 5.13 | Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial. ( Baykara, A; Baykara, B; Dirik, E; Gencer, O; Inal-Emiroglu, FN; Miral, S, 2008) |
| "The efficacy and tolerability of risperidone long-acting injectable were investigated in patients with schizophrenia or other psychotic disorders who had previously been symptomatically stable on olanzapine treatment." | 5.11 | Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. ( Frazzingaro, S; Gastpar, M; Latif, MA; Lombertie, ER; Masiak, M; Medori, R, 2005) |
| "This open-label, multicentre study investigated the clinical efficacy of liquid peroral risperidone in psychotic disorders, the patients' attitudes toward the study medication vs." | 5.11 | Risperidone liquid in psychotic disorders--efficacy and attitudes. ( Damjanović, A; Jasović-Gasić, M; Marić, N, 2005) |
| " The present study investigated the effect of risperidone on pre-existing severe tardive dyskinesia among 40 patients with chronic schizophrenia over 48 weeks." | 5.11 | Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. ( Bai, YM; Chen, JY; Chou, P; Lin, CC; Lin, CY; Yu, SC, 2005) |
| "Clinically stable subjects with schizophrenia or schizoaffective disorder participated in a 50-week, open-label trial of long-acting, injectable risperidone." | 5.11 | An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. ( Bossie, CA; Gharabawi, GM; Lasser, RA; Mao, L; Zhu, Y, 2005) |
| "The efficacy and safety of risperidone long-acting injectable (RLAI) was investigated in patients in the early phases of schizophrenia and schizoaffective disorders (< or = 3 years)." | 5.11 | Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. ( Andrezina, R; Gaebel, W; Glue, P; Masiak, M; Medori, R; Milanova, V; Parellada, E; Turner, MS, 2005) |
| "Atypical neuroleptics, including risperidone, are used to treat children with autism, despite limited efficacy and safety data." | 5.10 | Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. ( Choudhury, MS; Delaney, MA; Gifford, C; Maislin, G; Malone, RP, 2002) |
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 5.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| "Data on risperidone's efficacy and tolerability in adolescents with schizophrenia are scarce." | 5.10 | Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. ( Bensason, D; Carmon, E; Martin, A; Tyano, S; Weizman, A; Zalsman, G, 2003) |
| "A double-blind, placebo-controlled trial was performed to determine the efficacy and tolerability of 8 weeks of treatment with risperidone in the management of 48 adolescent and adult patients with Tourette syndrome." | 5.10 | Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial. ( Annable, L; Chouinard, G; Dion, Y; Sandor, P, 2002) |
| "The long-term safety and efficacy of long-acting injectable risperidone, the first long-acting second-generation antipsychotic, were evaluated in stable patients with schizophrenia." | 5.10 | Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. ( Chrzanowski, W; Eerdekens, M; Fleischhacker, WW; Gefvert, O; Karcher, K; Llorca, PM; Martin, S; Remington, G, 2003) |
| "The authors studied the incidence of tardive dyskinesia in elderly institutionalized patients with dementia being treated with risperidone." | 5.09 | Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. ( Jeste, DV; Kane, JM; Martinez, RA; Napolitano, J; Okamoto, A, 2000) |
| "Studies have shown that risperidone is safe and efficacious in young and middle-aged adults with chronic schizophrenia, but considerably fewer data are available on the treatment of elderly patients with schizophrenia or other psychotic disorders, particularly long-term outcomes." | 5.09 | A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. ( Barak, Y; Bray, G; Davidson, M; De Hooge, JD; Dose, M; Gagiano, CA; Harvey, PD; Haushofer, M; Vervarcke, J, 2000) |
| "The purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with treatment-refractory schizophrenia." | 5.09 | Risperidone in treatment-refractory schizophrenia. ( Green, MF; Marder, SR; Marshall, BD; Mintz, J; Wirshing, DA; Wirshing, WC, 1999) |
| "Combined data from double-blind risperidone studies were used to analyse the severity of extrapyramidal symptoms (EPS) associated with treatment in patients with chronic schizophrenia." | 5.09 | A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. ( Brecher, M; Lemmens, P; Van Baelen, B, 1999) |
| "The subjects were 62 patients hospitalized for acute exacerbations of schizophrenia and were randomly assigned to receive risperidone (mean dose, 7." | 5.08 | Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. ( Azorin, JM; Blin, O; Bouhours, P, 1996) |
| "The efficacy and safety of risperidone have previously been demonstrated in controlled clinical trials in hospitalized chronic schizophrenia patients who met strict research criteria." | 5.08 | A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial. ARCS Study Group. Assessment of Risperdal in a Clinical Setting. ( Brecher, M; Clyde, C; Jeste, DV; Jones, R; Klausner, M, 1997) |
| "In a double-blind study, 135 inpatients with a diagnosis of chronic schizophrenia were randomly assigned to 8 weeks of treatment with one of six parallel treatments: risperidone (a new central 5-hydroxytryptamine2 and dopamine D2 antagonist), 2, 6, 10, 16 mg/day; haloperidol, 20 mg/day; or placebo, after a single-blind placebo washout period." | 5.07 | A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. ( Addington, D; Arnott, W; Beauclair, L; Bloom, D; Chouinard, G; Jones, B; Labelle, A; MacEwan, GW; Remington, G, 1993) |
| " We aimed to establish the dose-response relationship for oral risperidone in relapsed schizophrenia." | 4.83 | Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. ( Ezewuzie, N; Taylor, D, 2006) |
| "Risperidone offers physicians the unique combination of extensive, published clinical experience and a good safety profile for treating patients with dementia who have symptoms of aggression, agitation, and psychosis." | 4.81 | Risperidone for the treatment of behavioral and psychological symptoms of dementia. ( Tune, LE, 2001) |
| " The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only)." | 4.80 | Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. ( , 1998) |
| "This 12-week open-label study was designed to investigate the pharmacokinetics and efficacy of a direct switch from a conventional depot to long-acting injectable risperidone in patients with schizophrenia and schizoaffective disorder." | 3.75 | Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders. ( Chen, CH; Chiu, CC; Huang, MC; Lai, YC; Pan, CH; Tsai, CJ, 2009) |
| "In total 56 patients acutely treated with haloperidol or risperidone either for the first episode of schizophrenia, schizophreniform or schizoaffective disorders, or for the relapse of these psychotic disorders after tapering their maintenance treatment, were genotyped for the 5-HTTLPR L and S alleles and for the new A/G functional variant within the L alelle (La/g)." | 3.74 | Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. ( Dolzan, V; Kastelic, M; Koprivsek, J; Mandelli, L; Plesnicar, BK; Serretti, A, 2008) |
| " Auditory hallucinations had developed 25 years previously, for which haloperidol had been prescribed." | 3.74 | Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam. ( Inada, T; Oda, T; Yamamoto, N, 2007) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 3.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "This case report illustrates the improvement of tardive dyskinesia (TD) and psychotic symptoms in an elderly Thai female with chronic schizophrenia with a long history of conventional antipsychotic exposure following the treatment with risperidone 2 mg/day." | 3.70 | Improvement of tardive dyskinesia with risperidone: a case report. ( Kooptiwoot, S; Settachan, T, 2000) |
| "A 26-year-old man with schizophrenia, disorganised type, and depression, developed severe tardive dyskinesia during treatment with risperidone and fluoxetine." | 3.70 | [Severe tardive dyskinesia during treatment with risperidone and fluoxetine]. ( Dubbelman, YD; Heeringa, M; Thung, FH, 1998) |
| "An open-label, multicentre study was conducted to assess the long-term efficacy and safety of risperidone in patients with chronic schizophrenia." | 3.70 | Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. ( Addington, DE; Gagiano, CA; Gaussares, C; Möller, HJ; Torres-Plank, JF; Von Knorring, L, 1998) |
| "Risperidone was shown to have significant anti-manic effects which was observed as early as week 1, following start of treatment." | 2.77 | Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania. ( Hsu, MC; Kuo, CC; Ouyang, WC; Yeh, IN, 2012) |
| "Ziprasidone was superior to risperidone in decreasing the PANSS positive symptoms subscore and the CGI-S score, and in increasing the GAF-F score." | 2.75 | Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. ( Johnsen, E; Jørgensen, HA; Kroken, RA; Wentzel-Larsen, T, 2010) |
| "Perphenazine was not significantly different in overall effectiveness, compared with quetiapine, risperidone, and ziprasidone." | 2.73 | What CATIE found: results from the schizophrenia trial. ( Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Rosenheck, RA; Stroup, TS; Swartz, MS, 2008) |
| "Risperidone was hypothesized to have better extrapyramidal tolerability and efficacy in treating negative symptoms." | 2.73 | Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. ( Braus, DF; Buchkremer, G; Gaebel, W; Gastpar, M; Heuser, I; Jäger, M; Klosterkötter, J; Kühn, KU; Maier, W; Möller, HJ; Ohmann, C; Riedel, M; Riesbeck, M; Schlösser, R; Schneider, F; Wickelmaier, F, 2008) |
| "In the second treatment year, relapse rates under continued neuroleptic treatment are compared with those under stepwise drug withdrawal substituting instead prodrome-based early intervention (intermittent treatment)." | 2.71 | Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. ( Bottlender, R; Buchkremer, G; Gaebel, W; Klingberg, S; Möller, HJ; Ohmann, C; Riesbeck, M; Von Wilmsdorff, M; Wölwer, W, 2004) |
| " The patients were treated with conventional antipsychotics for seven days after admission and were then randomised to the treatment arms with risperidone (4 mg/day) or with olanzapine (10 mg/day) at a fixed dosage in the first week and thereafter in flexible dosages for the remaining seven weeks." | 2.71 | Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia. ( Kores Plesnicar, B; Krajnc, I; Tomori, M; Zalar, B, 2003) |
| "Amoxapine was associated with less EPS and less prolactin elevation than risperidone." | 2.71 | Amoxapine as an atypical antipsychotic: a comparative study vs risperidone. ( Apiquian, R; de la Fuente-Sandoval, C; Fresan, A; Herrera-Estrella, M; Kapur, S; Nicolini, H; Ulloa, RE; Vazquez, A, 2005) |
| "The risperidone dose was started at 2 mg/day and gradually increased to 6 mg/day over 6 weeks; the 6-mg/day dose was maintained for the remaining 6 weeks of the study." | 2.71 | Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. ( Bai, YM; Lin, CC; Yu, SC, 2003) |
| "The treatment of schizoaffective disorder is often complicated by the variety of symptoms that contribute to its pathology." | 2.71 | Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. ( Bossie, CA; Eerdekens, M; Gharabawi, G; Lasser, R; Nasrallah, HA, 2004) |
| " Adding risperidone to mirtazapine probably does not necessitate a change of the dosage of either drug, but more extensive investigations are needed." | 2.69 | Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study. ( Doorschot, CH; Loonen, AJ; Oostelbos, MC; Sitsen, JM, 1999) |
| "Risperidone (6 to 16 mg)-treated patients showed significantly (p < 0." | 2.68 | Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. ( Chouinard, G, 1995) |
| " They responded well to the reduction in dosage or to withdrawal of the apparent causing agent." | 2.49 | [Medication-related oculogyric crises: a description of four cases and a review of the literature]. ( Campistol, J; Darling, A; Perez-Duenas, B; Poo, P, 2013) |
| " Mean CLZ dosage during the combined treatment was 474." | 2.43 | Risperidone augmentation of clozapine: a critical review. ( Christodoulou, GN; Ferentinos, PP; Havaki-Kontaxaki, BJ; Kontaxakis, VP; Paplos, KG; Pappa, DA, 2006) |
| " Surprisingly, there has been little relationship between the pivotal trials designed for FDA approval and current dosing strategies in broader clinical settings." | 2.41 | New antipsychotic medications: more than old wine and new bottles. ( Schulz, SC, 2000) |
| "Risperidone appears to be an effective therapy, but several authors report cases of TD during treatment." | 2.41 | Tardive dyskinesias and antipsychotics: a review. ( Bayle, FJ; Chereau, I; Lancon, C; Llorca, PM, 2002) |
| "In 2 pivotal trials comparing risperidone with placebo, the risk of adverse events was similar in both treatment groups when risperidone was given at the optimal clinical dose (1 mg/day)." | 2.41 | Long-term safety of risperidone. ( Davidson, M, 2001) |
| "Although the risk of developing lethal neuroleptic malignant syndrome may be diminished with atypical drugs, clinicians must remain alert to the signs of this disorder." | 2.41 | Movement disorders associated with atypical antipsychotic drugs. ( Campbell, EC; Caroff, SN; Mann, SC; Sullivan, KA, 2002) |
| " Dosing requirements for elderly patients tend to be much lower than those for younger adults." | 2.40 | Conventional vs. newer antipsychotics in elderly patients. ( Harris, MJ; Jeste, DV; Lacro, J; Lohr, JB; Rockwell, E, 1999) |
| " Considerable progress has been made in improving the motor side effect profile with the advent of clozapine and risperidone." | 2.39 | Side effect profiles of new antipsychotic agents. ( Casey, DE, 1996) |
| "Risperidone has these pharmacologic properties." | 2.39 | Extrapyramidal side effects and tolerability of risperidone: a review. ( Owens, DG, 1994) |
| " Side-effects can be minimized by optimization of clinical strategies, including choice of appropriate drug, slow titration and dosage reduction." | 2.39 | Minimizing the non-extrapyramidal side-effects of antipsychotics. ( Keks, NA, 1996) |
| "A number of new agents to treat schizophrenia have been, or will soon be, introduced that address the limitations of traditional neuroleptics." | 2.38 | New antipsychotic medications: do research results relate to clinical practice? ( MacEwan, GW, 1993) |
| "Antipsychotic drugs can induce various undesirable adverse motor reactions, such as extrapyramidal side effects (EPS)." | 1.43 | Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations? ( Gründer, G; Haen, E; Hiemke, C; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Schruers, KR; Stegmann, B; Veselinovic, T, 2016) |
| " EPS were assessed at baseline and 4, 8, and 12 weeks after naturalistic SGA initiation for schizophrenia, mood, disruptive behavior, and autism spectrum disorders using the Simpson-Angus Scale (SAS), Barnes Akathisia Scale, Abnormal Involuntary Movement Scale (AIMS), and Treatment Emergent Side Effect Scale." | 1.42 | Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. ( Al-Jadiri, A; Azzo, S; Carbon, M; Correll, CU; Kane, JM; Kapoor, S; Saito, E; Sarkaria, T; Sheridan, E, 2015) |
| "Risperidone was associated with higher increases in DyskinesiaS compared with quetiapine (P < 0." | 1.42 | Neurological Adverse Effects of Antipsychotics in Children and Adolescents. ( Alda, JA; Andrés Nestares, P; Arango, C; Baeza, I; Cantarero, CM; Castro-Fornieles, J; de la Serna, E; Garcia-Amador, M; Merchán-Naranjo, J; Moreno, C; Muñoz, D; Tapia, C, 2015) |
| " However, researchers lack a standardised method to compare different drugs for common adverse effects on the nervous system." | 1.39 | Assessment of adverse effects of neurotropic drugs in monkeys with the "drug effects on the nervous system" (DENS) scale. ( Menniti, FS; Papa, SM; Schmidt, CJ; Shaffer, CL; Uthayathas, S, 2013) |
| "Domperidone is a dopamine D₂ receptor antagonist that does not usually cross the blood-brain barrier." | 1.37 | Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia. ( Bocti, C; Hottin, P; Landry, J; Roy-Desruisseaux, J; Tessier, D; Trudel, JF, 2011) |
| "Haloperidol patients were more often single and institutionalised, less educated, had more residual schizophrenia, were longer hospitalised in the previous year, took more corrective and psychotropic drugs and had more extrapyramidal symptoms (EPS) and gynaecomastia (all significantly)." | 1.35 | Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. ( Albert, A; De Graeve, D; Gillain, B; Peuskens, J; Van Vleymen, B, 2009) |
| " The present study compares the effect of chronic administration of typical and atypical antipsychotics on neurochemical profile in rat forebrain." | 1.34 | Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia. ( Bishnoi, M; Chopra, K; Kulkarni, SK; Kumar, A, 2007) |
| " Failure in switching to monotherapy was associated with higher dosage of antipsychotics at baseline." | 1.33 | Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia. ( Kunugi, H; Murray, RM; Nakanishi, S; Nojima, S; Ogawa, T; Takahashi, T, 2006) |
| "Risperidone-treated animals showed a catalepsy-like phenotype, which differed to that of haloperidol-treated rats, indicating that processes other than the anticipated dopaminergic mechanisms are underlying this phenomenon." | 1.33 | Behavioural effects of chronic haloperidol and risperidone treatment in rats. ( Dedova, I; Duffy, L; Karl, T; Matsumoto, I; O'brien, E, 2006) |
| "Risperidone is a second-generation antipsychotic that lacks acute motor side effects at low doses (<6 mg/day), but above this level is associated with parkinsonism and akathesia." | 1.33 | Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia. ( Cooper, T; Gao, XM; Suckow, RF; Tamminga, CA, 2006) |
| "Similarly to acute rat catalepsy, "early onset" vacuous chewing movements (VCMs) induced by subchronic treatment with antipsychotic have recently been proposed as a model of human extrapyramidal symptoms." | 1.32 | Haloperidol versus risperidone on rat "early onset" vacuous chewing. ( Bartholini, F; Casti, P; Casu, MA; Congeddu, E; Marchese, G; Pani, L; Ruiu, S; Tambaro, S, 2004) |
| "Converging evidence indicates that, in controlled drug trials, individuals receiving novel antipsychotic medications have fewer adverse effects than those receiving conventional antipsychotic medications." | 1.31 | Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study. ( Bromet, EJ; Davidson, M; Rabinowitz, J, 2001) |
| "Risperidone (4 mg/day) was added to her drug regimen and after increasing the dosage to 6 mg/day, she began to exhibit retrocollis." | 1.31 | Tardive dystonia provoked by concomitantly administered risperidone. ( Hori, M; Hori, T; Kawanishi, Y; Shiraishi, H; Suzuki, T; Tachikawa, H, 2000) |
| "With risperidone treatment, the vocalizations diminished to less than 20% of baseline ratings." | 1.30 | The use of risperidone in severely demented patients with persistent vocalizations. ( Honer, WG; Kopala, LC, 1997) |
| "In contrast, tardive dystonia is a long-lasting menace in the course of antipsychotic treatment, for which there is no established therapy." | 1.30 | Managing antipsychotic-induced acute and tardive dystonia. ( Raja, M, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 68 (34.69) | 18.2507 |
| 2000's | 106 (54.08) | 29.6817 |
| 2010's | 22 (11.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, H | 1 |
| Xu, J | 1 |
| Kumar, M | 1 |
| Mattison, R | 1 |
| Baweja, R | 1 |
| Uthayathas, S | 1 |
| Shaffer, CL | 1 |
| Menniti, FS | 1 |
| Schmidt, CJ | 1 |
| Papa, SM | 1 |
| Suzuki, H | 1 |
| Gen, K | 1 |
| Inoue, Y | 1 |
| Hibino, H | 1 |
| Mikami, A | 1 |
| Matsumoto, H | 1 |
| Mikami, K | 1 |
| Kwak, YT | 1 |
| Yang, Y | 1 |
| Koo, MS | 1 |
| Uchida, H | 1 |
| Suzuki, T | 2 |
| Graff-Guerrero, A | 1 |
| Mulsant, BH | 1 |
| Pollock, BG | 1 |
| Arenovich, T | 1 |
| Rajji, TK | 1 |
| Mamo, DC | 1 |
| Carbon, M | 1 |
| Kapoor, S | 1 |
| Sheridan, E | 1 |
| Al-Jadiri, A | 1 |
| Azzo, S | 1 |
| Sarkaria, T | 1 |
| Kane, JM | 6 |
| Saito, E | 1 |
| Correll, CU | 2 |
| Garcia-Amador, M | 1 |
| Merchán-Naranjo, J | 1 |
| Tapia, C | 1 |
| Moreno, C | 1 |
| Castro-Fornieles, J | 1 |
| Baeza, I | 1 |
| de la Serna, E | 1 |
| Alda, JA | 1 |
| Muñoz, D | 1 |
| Andrés Nestares, P | 1 |
| Cantarero, CM | 1 |
| Arango, C | 1 |
| Schoretsanitis, G | 1 |
| Haen, E | 1 |
| Hiemke, C | 1 |
| Gründer, G | 1 |
| Stegmann, B | 1 |
| Schruers, KR | 1 |
| Veselinovic, T | 1 |
| Lammertz, SE | 1 |
| Paulzen, M | 1 |
| Fusar-Poli, RR | 1 |
| Dolzan, V | 1 |
| Serretti, A | 1 |
| Mandelli, L | 1 |
| Koprivsek, J | 1 |
| Kastelic, M | 1 |
| Plesnicar, BK | 1 |
| Casey, DE | 3 |
| Sands, EE | 1 |
| Heisterberg, J | 1 |
| Yang, HM | 1 |
| Aukst-Margetić, B | 1 |
| Margetić, B | 1 |
| Peuskens, J | 1 |
| Gillain, B | 1 |
| De Graeve, D | 1 |
| Van Vleymen, B | 1 |
| Albert, A | 1 |
| Lamkin, S | 1 |
| Buhl, D | 1 |
| Peritogiannis, V | 2 |
| Tsouli, S | 2 |
| Lai, YC | 1 |
| Huang, MC | 1 |
| Chen, CH | 2 |
| Tsai, CJ | 1 |
| Pan, CH | 1 |
| Chiu, CC | 1 |
| Rajarethinam, R | 1 |
| Dziuba, J | 1 |
| Manji, S | 1 |
| Pizzuti, A | 1 |
| Lachover, L | 1 |
| Keshavan, M | 1 |
| Kumar, A | 2 |
| Strech, D | 1 |
| Haas, M | 1 |
| Unis, AS | 1 |
| Armenteros, J | 1 |
| Copenhaver, MD | 1 |
| Quiroz, JA | 1 |
| Kushner, SF | 1 |
| Hebebrand, J | 1 |
| Johnsen, E | 1 |
| Kroken, RA | 1 |
| Wentzel-Larsen, T | 1 |
| Jørgensen, HA | 1 |
| Chan, HY | 1 |
| Chiang, SC | 1 |
| Chang, CJ | 1 |
| Gau, SS | 1 |
| Chen, JJ | 1 |
| Hwu, HG | 1 |
| Lai, MS | 1 |
| Mendhekar, DN | 2 |
| Inamdar, A | 1 |
| Potkin, SG | 1 |
| Daniel, DG | 3 |
| Buckley, PF | 1 |
| Crespo-Facorro, B | 1 |
| Pérez-Iglesias, R | 1 |
| Mata, I | 1 |
| Ramirez-Bonilla, M | 1 |
| Martínez-Garcia, O | 1 |
| Pardo-Garcia, G | 1 |
| Caseiro, O | 1 |
| Pelayo-Terán, JM | 1 |
| Vázquez-Barquero, JL | 1 |
| Li, H | 1 |
| Rui, Q | 1 |
| Ning, X | 1 |
| Xu, H | 1 |
| Gu, N | 1 |
| Woerner, MG | 2 |
| Alvir, JM | 1 |
| Greenwald, B | 1 |
| Delman, H | 1 |
| Roy-Desruisseaux, J | 1 |
| Landry, J | 1 |
| Bocti, C | 1 |
| Tessier, D | 1 |
| Hottin, P | 1 |
| Trudel, JF | 1 |
| Ouyang, WC | 1 |
| Hsu, MC | 1 |
| Yeh, IN | 1 |
| Kuo, CC | 1 |
| Chung, AK | 1 |
| Darling, A | 1 |
| Poo, P | 1 |
| Perez-Duenas, B | 1 |
| Campistol, J | 1 |
| Suzuki, E | 1 |
| Obata, M | 1 |
| Yoshida, Y | 1 |
| Miyaoka, H | 1 |
| Schwartz, TL | 1 |
| Saba, M | 1 |
| Hardoby, W | 1 |
| Virk, S | 1 |
| Masand, PS | 1 |
| Kores Plesnicar, B | 1 |
| Zalar, B | 1 |
| Tomori, M | 1 |
| Krajnc, I | 1 |
| Gothelf, D | 1 |
| Apter, A | 1 |
| Reidman, J | 1 |
| Brand-Gothelf, A | 1 |
| Bloch, Y | 1 |
| Gal, G | 1 |
| Kikinzon, L | 1 |
| Tyano, S | 2 |
| Weizman, R | 1 |
| Ratzoni, G | 1 |
| Carvalho, RC | 1 |
| Silva, RH | 1 |
| Abílio, VC | 1 |
| Barbosa, PN | 1 |
| Frussa-Filho, R | 1 |
| Zolk, O | 1 |
| Thürauf, N | 1 |
| Philipp, M | 2 |
| Lesch, OM | 2 |
| Schmauss, M | 2 |
| Dose, M | 2 |
| Glaser, T | 1 |
| Apiquian, R | 2 |
| Fresán, A | 2 |
| Herrera, K | 1 |
| Ulloa, RE | 2 |
| Lóyzaga, C | 1 |
| de la Fuente-Sandoval, C | 2 |
| Gutiérrez, D | 1 |
| Nicolini, H | 2 |
| Zalsman, G | 1 |
| Carmon, E | 1 |
| Martin, A | 1 |
| Bensason, D | 1 |
| Weizman, A | 2 |
| Bai, YM | 3 |
| Yu, SC | 2 |
| Lin, CC | 3 |
| Fleischhacker, WW | 1 |
| Eerdekens, M | 3 |
| Karcher, K | 1 |
| Remington, G | 4 |
| Llorca, PM | 2 |
| Chrzanowski, W | 1 |
| Martin, S | 1 |
| Gefvert, O | 1 |
| Marchese, G | 2 |
| Bartholini, F | 2 |
| Casu, MA | 2 |
| Ruiu, S | 2 |
| Casti, P | 1 |
| Congeddu, E | 1 |
| Tambaro, S | 1 |
| Pani, L | 2 |
| Schwartz, M | 2 |
| Hocherman, S | 1 |
| Kwon, H | 1 |
| Dossenbach, M | 1 |
| Erol, A | 1 |
| el Mahfoud Kessaci, M | 1 |
| Shaheen, MO | 1 |
| Sunbol, MM | 1 |
| Boland, J | 1 |
| Hodge, A | 1 |
| O'Halloran, RA | 1 |
| Bitter, I | 1 |
| Bressan, RA | 1 |
| Jones, HM | 1 |
| Pilowsky, LS | 1 |
| Gaebel, W | 3 |
| Möller, HJ | 5 |
| Buchkremer, G | 2 |
| Ohmann, C | 2 |
| Riesbeck, M | 2 |
| Wölwer, W | 1 |
| Von Wilmsdorff, M | 1 |
| Bottlender, R | 1 |
| Klingberg, S | 1 |
| Jeste, DV | 6 |
| Karama, S | 1 |
| Lal, S | 1 |
| Lasser, R | 1 |
| Bossie, CA | 3 |
| Gharabawi, G | 1 |
| Nasrallah, HA | 1 |
| Bobes, J | 1 |
| Cañas, F | 1 |
| Rejas, J | 1 |
| Mackell, J | 1 |
| Ellard, J | 1 |
| Chen, JY | 2 |
| Lin, CY | 1 |
| Chou, P | 1 |
| Witschy, JK | 1 |
| Winter, AS | 1 |
| Schooler, N | 1 |
| Rabinowitz, J | 3 |
| Davidson, M | 4 |
| Emsley, R | 2 |
| Harvey, PD | 2 |
| Kopala, L | 1 |
| McGorry, PD | 1 |
| Van Hove, I | 1 |
| Swyzen, W | 1 |
| De Smedt, G | 1 |
| Gharabawi, GM | 2 |
| Zhu, Y | 2 |
| Mao, L | 1 |
| Lasser, RA | 1 |
| Herrera-Estrella, M | 1 |
| Vazquez, A | 1 |
| Kapur, S | 1 |
| Yang, YK | 1 |
| Tarn, YH | 2 |
| Wang, TY | 1 |
| Liu, CY | 1 |
| Laio, YC | 1 |
| Chou, YH | 1 |
| Lee, SM | 1 |
| Chen, CC | 1 |
| Parellada, E | 1 |
| Andrezina, R | 1 |
| Milanova, V | 1 |
| Glue, P | 2 |
| Masiak, M | 2 |
| Turner, MS | 1 |
| Medori, R | 4 |
| Gastpar, M | 2 |
| Latif, MA | 2 |
| Frazzingaro, S | 1 |
| Lombertie, ER | 1 |
| de Leon, J | 1 |
| Susce, MT | 1 |
| Pan, RM | 1 |
| Koch, WH | 1 |
| Wedlund, PJ | 1 |
| Ezewuzie, N | 1 |
| Taylor, D | 1 |
| Ehrt, U | 1 |
| Fritze, F | 1 |
| Aarsland, D | 1 |
| Eberhard, J | 1 |
| Lindström, E | 1 |
| Levander, S | 1 |
| Gao, XM | 1 |
| Cooper, T | 1 |
| Suckow, RF | 1 |
| Tamminga, CA | 1 |
| Margolese, HC | 1 |
| Chouinard, G | 5 |
| Kolivakis, TT | 1 |
| Beauclair, L | 2 |
| Miller, R | 2 |
| Annable, L | 2 |
| Jasović-Gasić, M | 1 |
| Marić, N | 1 |
| Damjanović, A | 1 |
| Essock, SM | 1 |
| Covell, NH | 1 |
| Jackson, CT | 1 |
| Feroz-Nainar, C | 1 |
| Roy, M | 1 |
| Karl, T | 1 |
| Duffy, L | 1 |
| O'brien, E | 1 |
| Matsumoto, I | 1 |
| Dedova, I | 1 |
| Sutor, B | 1 |
| Hansen, MR | 1 |
| Black, JL | 1 |
| Kontaxakis, VP | 1 |
| Ferentinos, PP | 1 |
| Havaki-Kontaxaki, BJ | 1 |
| Paplos, KG | 1 |
| Pappa, DA | 1 |
| Christodoulou, GN | 2 |
| Böker, H | 1 |
| Brandenberger, M | 1 |
| Schopper, C | 1 |
| Nakanishi, S | 1 |
| Kunugi, H | 1 |
| Murray, RM | 1 |
| Nojima, S | 1 |
| Ogawa, T | 1 |
| Takahashi, T | 1 |
| Harada, K | 1 |
| Saito, T | 1 |
| Stevens, HE | 1 |
| Limosin, F | 1 |
| Bishnoi, M | 1 |
| Chopra, K | 1 |
| Kulkarni, SK | 1 |
| Ruhrmann, S | 1 |
| Kissling, W | 1 |
| Seemann, U | 1 |
| Linden, M | 1 |
| Eich, FX | 1 |
| Pyrkosch, L | 1 |
| Hollis, CP | 1 |
| Thompson, A | 1 |
| Urbano, M | 1 |
| Spiegel, D | 1 |
| Rai, A | 1 |
| Marinis, TD | 1 |
| Saleem, PT | 1 |
| Arnoldussen, WJ | 1 |
| Teijeiro, R | 1 |
| Lex, A | 1 |
| Miral, S | 1 |
| Gencer, O | 1 |
| Inal-Emiroglu, FN | 1 |
| Baykara, B | 1 |
| Baykara, A | 1 |
| Dirik, E | 1 |
| Yamamoto, N | 1 |
| Oda, T | 1 |
| Inada, T | 1 |
| Malone, RP | 3 |
| Harvey, JA | 1 |
| Swartz, MS | 1 |
| Stroup, TS | 1 |
| McEvoy, JP | 1 |
| Davis, SM | 1 |
| Rosenheck, RA | 1 |
| Keefe, RS | 1 |
| Hsiao, JK | 1 |
| Lieberman, JA | 2 |
| Riedel, M | 1 |
| Jäger, M | 1 |
| Wickelmaier, F | 1 |
| Maier, W | 1 |
| Kühn, KU | 1 |
| Heuser, I | 1 |
| Klosterkötter, J | 1 |
| Braus, DF | 1 |
| Schlösser, R | 1 |
| Schneider, F | 1 |
| Jeffries, JJ | 1 |
| MacEwan, GW | 2 |
| Kerwin, RW | 1 |
| Owens, DG | 1 |
| Adams, M | 1 |
| Vainer, JL | 1 |
| Bélanger, MC | 1 |
| Turnier, L | 1 |
| Beaudry, P | 1 |
| Roy, JY | 1 |
| Kopala, LC | 3 |
| Honer, WG | 2 |
| Addington, DE | 2 |
| Toews, JA | 1 |
| Addington, JM | 1 |
| Moseley, C | 1 |
| Rosenfield, S | 1 |
| Wolf, S | 1 |
| Nawroz, S | 1 |
| Jones, B | 1 |
| Bloom, D | 1 |
| Addington, D | 1 |
| Labelle, A | 1 |
| Arnott, W | 1 |
| Rich, SS | 1 |
| Friedman, JH | 2 |
| Ott, BR | 1 |
| Buzan, RD | 1 |
| Smith, K | 1 |
| Hyde, T | 1 |
| Egan, M | 1 |
| Sheitman, BB | 1 |
| Benazzi, F | 1 |
| Rangwani, SR | 1 |
| Gupta, S | 1 |
| Burke, WJ | 1 |
| Potter, J | 1 |
| Blin, O | 1 |
| Azorin, JM | 1 |
| Bouhours, P | 1 |
| Iruela, LM | 1 |
| Anand, VS | 1 |
| Dewan, MJ | 1 |
| Feeney, DJ | 1 |
| Klykylo, W | 1 |
| Keks, NA | 1 |
| Gwinn, KA | 1 |
| Caviness, JN | 1 |
| Simon, EW | 1 |
| Blubaugh, KM | 1 |
| Pippidis, M | 1 |
| Rowan, AB | 1 |
| Brown, ES | 1 |
| Koponen, HJ | 1 |
| Klausner, M | 1 |
| Brecher, M | 2 |
| Clyde, C | 1 |
| Jones, R | 1 |
| Edleman, RJ | 1 |
| Khan, BU | 1 |
| Tran, PV | 1 |
| Hamilton, SH | 1 |
| Kuntz, AJ | 1 |
| Potvin, JH | 1 |
| Andersen, SW | 1 |
| Beasley, C | 1 |
| Tollefson, GD | 1 |
| Gutierrez-Esteinou, R | 1 |
| Grebb, JA | 1 |
| Meco, G | 1 |
| Fabrizio, E | 1 |
| Alessandri, A | 1 |
| Vanacore, N | 1 |
| Bonifati, V | 1 |
| Haberfellner, EM | 1 |
| Saran, BM | 1 |
| Caley, CF | 1 |
| Silberbauer, C | 1 |
| Fischer, P | 1 |
| Tauscher, J | 1 |
| Küfferle, B | 1 |
| Raja, M | 1 |
| Gagiano, CA | 2 |
| Von Knorring, L | 1 |
| Torres-Plank, JF | 1 |
| Gaussares, C | 1 |
| Lewis, R | 1 |
| Dubbelman, YD | 1 |
| Thung, FH | 1 |
| Heeringa, M | 1 |
| Sherr, JD | 1 |
| Thaker, G | 1 |
| Kinon, BJ | 1 |
| Demb, HB | 1 |
| Nguyen, KT | 1 |
| Rockwell, E | 2 |
| Harris, MJ | 2 |
| Lohr, JB | 1 |
| Lacro, J | 1 |
| Levin, T | 1 |
| Heresco-Levy, U | 1 |
| Lemmens, P | 1 |
| Van Baelen, B | 1 |
| Campbell, M | 1 |
| Chong, SA | 1 |
| Tan, CH | 1 |
| Lacro, JP | 1 |
| Bailey, A | 1 |
| Caligiuri, MP | 1 |
| Krebs, MO | 1 |
| Olie, JP | 1 |
| Megna, JL | 1 |
| Dewan, M | 1 |
| Hong, KS | 1 |
| Cheong, SS | 1 |
| Woo, JM | 1 |
| Kim, E | 1 |
| Carroll, NB | 1 |
| Boehm, KE | 1 |
| Strickland, RT | 1 |
| Wirshing, DA | 1 |
| Marshall, BD | 1 |
| Green, MF | 1 |
| Mintz, J | 1 |
| Marder, SR | 1 |
| Wirshing, WC | 2 |
| Lykouras, L | 1 |
| Yannakis, R | 1 |
| Hatzimanolis, J | 1 |
| Snoddgrass, PL | 1 |
| Labbate, LA | 1 |
| Loonen, AJ | 1 |
| Doorschot, CH | 1 |
| Oostelbos, MC | 1 |
| Sitsen, JM | 1 |
| Silver, H | 1 |
| Aharon, N | 1 |
| Schulz, SC | 1 |
| Glazer, WM | 2 |
| Simpson, GM | 1 |
| Spivak, M | 1 |
| Smart, M | 1 |
| Kumar, S | 1 |
| Malone, DM | 1 |
| Naber, D | 1 |
| Vervarcke, J | 1 |
| De Hooge, JD | 1 |
| Bray, G | 1 |
| Barak, Y | 1 |
| Haushofer, M | 1 |
| Okamoto, A | 1 |
| Napolitano, J | 1 |
| Martinez, RA | 1 |
| Lore, C | 1 |
| Bassitt, DP | 1 |
| de Souza Lobo Garcia, L | 1 |
| Tachikawa, H | 1 |
| Kawanishi, Y | 1 |
| Hori, M | 1 |
| Hori, T | 1 |
| Shiraishi, H | 1 |
| Mullen, A | 1 |
| Kooptiwoot, S | 1 |
| Settachan, T | 1 |
| Hesslinger, B | 1 |
| Walden, J | 1 |
| Normann, C | 1 |
| Morgenstern, H | 1 |
| Woods, SW | 1 |
| Agarwal, V | 1 |
| Kumar, P | 1 |
| Ipekçi, S | 1 |
| Birsöz, S | 1 |
| Chaplin, RH | 1 |
| Tune, LE | 1 |
| Pyng, LY | 1 |
| Chroni, E | 1 |
| Lekka, NP | 1 |
| Tsibri, E | 1 |
| Economou, A | 1 |
| Paschalis, C | 1 |
| Dion, Y | 1 |
| Sandor, P | 1 |
| Bromet, EJ | 1 |
| Maislin, G | 1 |
| Choudhury, MS | 1 |
| Gifford, C | 1 |
| Delaney, MA | 1 |
| Caroff, SN | 1 |
| Mann, SC | 1 |
| Campbell, EC | 1 |
| Sullivan, KA | 1 |
| Saba, P | 1 |
| Gessa, GL | 1 |
| Gil-ad, I | 1 |
| Shtaif, B | 1 |
| Shiloh, R | 1 |
| Davis, JM | 1 |
| Chen, N | 1 |
| Chereau, I | 1 |
| Bayle, FJ | 1 |
| Lancon, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Risperidone for the Treatment of Schizophrenia in Adolescents[NCT00088075] | Phase 3 | 160 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting.[NCT00932529] | Phase 4 | 226 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Randomized Controlled Trial of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia[NCT00621998] | Phase 4 | 60 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| Behavioral Therapy for Children and Adolescents With Tourette Syndrome: A Randomized Controlled Trial in Taiwan[NCT03621059] | 46 participants (Actual) | Interventional | 2015-01-01 | Completed | |||
| Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepine in Patients With First-Episode Schizophrenia After One Year Maintenance Treatment Under Further Maintenance Treatment vs. Stepwise Discontinued Drugs[NCT00159133] | Phase 4 | 71 participants (Anticipated) | Interventional | 2001-11-30 | Completed | ||
| One Year Maintenance Treatment With Low Dose Haloperidol vs. Risperidone in First-Episode Schizophrenia[NCT00159081] | Phase 4 | 159 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| Maintenance Treatment vs. Stepwise Drug Discontinuation After One Year of Maintenance Treatment in First-Episode Schizophrenia[NCT00159120] | Phase 4 | 71 participants (Anticipated) | Interventional | 2001-11-30 | Completed | ||
| Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study[NCT00837707] | Phase 4 | 25 participants (Anticipated) | Interventional | 2008-06-30 | Recruiting | ||
| Risperidone Versus Haloperidol Versus Placebo in the Treatment of Chronic Schizophrenia[NCT00249132] | Phase 3 | 523 participants (Actual) | Interventional | Completed | |||
| Quetiapine in the Treatment of Psychotic Depression - a Pilot Study[NCT00751504] | Phase 3 | 16 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
37 reviews available for risperidone and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Wendan decoction (Traditional Chinese medicine) for schizophrenia.
Topics: Antipsychotic Agents; Chlorpromazine; Drug Therapy, Combination; Drugs, Chinese Herbal; Dyskinesia, | 2017 |
Zuclopenthixol dihydrochloride for schizophrenia.
Topics: Antipsychotic Agents; Clopenthixol; Dyskinesia, Drug-Induced; Humans; Randomized Controlled Trials a | 2009 |
[Neuroleptic adverse effects with emphasis on weight gain].
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Brain; Cardiomyopathies; Child; Clozapine; Dyskin | 2009 |
[Medication-related oculogyric crises: a description of four cases and a review of the literature].
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Child; Child Behavior Disorders; Ch | 2013 |
[Risperidone].
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Dopamine Antagonists; Dyskinesia, Drug-Induce | 2003 |
Antipsychotic-induced rabbit syndrome: epidemiology, management and pathophysiology.
Topics: Animals; Antipsychotic Agents; Clozapine; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; | 2004 |
Tardive dyskinesia rates with atypical antipsychotics in older adults.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dose | 2004 |
Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Me | 2006 |
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Dyskinesia, Drug | 2005 |
Risperidone augmentation of clozapine: a critical review.
Topics: Antipsychotic Agents; Clozapine; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Dysk | 2006 |
[The use of atypical antipsychotics in the long-term care of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; | 2006 |
Ethical issues in drug selection for schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Dyskinesia, Drug-Induced; Ethics, Medical; Humans; Informed Consent | 1993 |
New antipsychotic medications: do research results relate to clinical practice?
Topics: Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Dyskinesia, Drug-Induced; Humans; Isoxazo | 1993 |
The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research.
Topics: Antipsychotic Agents; Brain; Clozapine; Dyskinesia, Drug-Induced; Extrapyramidal Tracts; Humans; Iso | 1994 |
Extrapyramidal side effects and tolerability of risperidone: a review.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; D | 1994 |
[Recent developments in antipsychotic medication].
Topics: Antipsychotic Agents; Brain; Dyskinesia, Drug-Induced; Humans; Receptors, Dopamine D2; Receptors, Se | 1995 |
Side effect profiles of new antipsychotic agents.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; | 1996 |
Spontaneous and drug-induced movement disorders in schizophrenia.
Topics: Antipsychotic Agents; Cholinergic Antagonists; Chronic Disease; Dose-Response Relationship, Drug; Dy | 1996 |
Minimizing the non-extrapyramidal side-effects of antipsychotics.
Topics: Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dys | 1996 |
Risperidone: an analysis of the first three years in general use.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dopamine Antagonists; Drug Resistance; Dyskinesia, D | 1997 |
Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms.
Topics: Adolescent; Adolescent Psychiatry; Age Factors; Antipsychotic Agents; Benzodiazepines; Cholinergic F | 1998 |
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Central Nervous Syst | 1998 |
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Tri | 1998 |
The routine use of atypical antipsychotic agents: maintenance treatment.
Topics: Antipsychotic Agents; Benzodiazepines; Caregivers; Dyskinesia, Drug-Induced; Humans; Olanzapine; Pir | 1998 |
Conventional vs. newer antipsychotics in elderly patients.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia; Dibenzothiazepines; Dose-Re | 1999 |
Tardive dyskinesia and atypical antipsychotic drugs.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; | 1999 |
Tardive dyskinesia in affective disorders.
Topics: Adult; Affective Disorders, Psychotic; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipol | 1999 |
Two cases of risperidone-induced tardive dyskinesia and a review of the literature.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Risperidone | 1999 |
New antipsychotic medications: more than old wine and new bottles.
Topics: Agranulocytosis; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzot | 2000 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; | 2000 |
The treatment of tardive dyskinesia and tardive dystonia.
Topics: Adult; Akathisia, Drug-Induced; Algorithms; Antipsychotic Agents; Benzodiazepines; Clozapine; Decisi | 2000 |
[New i.e. atypical neuroleptic agents for negative symptoms of schizophrenia: results and methodological problems of evaluation].
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; | 2000 |
Movement disorders associated with neuroleptic treatment.
Topics: Age Factors; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; | 2001 |
Long-term safety of risperidone.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Cholinesterase Inhibitors; Clinical Trials as To | 2001 |
Risperidone for the treatment of behavioral and psychological symptoms of dementia.
Topics: Aged; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Cognition | 2001 |
Movement disorders associated with atypical antipsychotic drugs.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; | 2002 |
Tardive dyskinesias and antipsychotics: a review.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; Humans; Ola | 2002 |
48 trials available for risperidone and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial.
Topics: Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Cognition Disorders; Drug Substitution; Dyskine | 2014 |
Therapeutic window for striatal dopamine D(2/3) receptor occupancy in older patients with schizophrenia: a pilot PET study.
Topics: Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Func | 2014 |
Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzoxazoles; Body Weight; Cholesterol; Dose-Response Re | 2008 |
A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia.
Topics: Adolescent; Adolescent Behavior; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blin | 2009 |
Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Administration Schedule; Dysk | 2010 |
A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Dose-Response Relation | 2010 |
A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Resistance; Drug-Related Side Effects and Adv | 2011 |
Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; | 2011 |
A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Data Interpretation, Statistical; Delayed-Action Preparatio | 2011 |
Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania.
Topics: Acute Disease; Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Body Wei | 2012 |
Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-I | 2003 |
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Depression; Dopamine Antagonists; Dyskinesia, Dru | 2003 |
[Comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia].
Topics: Antipsychotic Agents; Chronic Disease; Depression; Double-Blind Method; Dyskinesia, Drug-Induced; Fl | 2003 |
Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Dose-Response Rel | 2003 |
Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug- | 2003 |
Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Me | 2003 |
Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
Topics: Administration, Oral; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and | 2003 |
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germ | 2004 |
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germ | 2004 |
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germ | 2004 |
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germ | 2004 |
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germ | 2004 |
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germ | 2004 |
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germ | 2004 |
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germ | 2004 |
Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Germ | 2004 |
Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Delayed-Act | 2004 |
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Dyskinesia, Drug-Induced; Follow-Up St | 2004 |
Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female | 2005 |
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Ind | 2005 |
An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antipsychotic Agents; Delayed-Action Preparati | 2005 |
Amoxapine as an atypical antipsychotic: a comparative study vs risperidone.
Topics: Adolescent; Adult; Amoxapine; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind M | 2005 |
Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
Topics: Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Female; Hu | 2005 |
Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Delayed-Action Preparati | 2005 |
Risperidone liquid in psychotic disorders--efficacy and attitudes.
Topics: Administration, Oral; Adult; Aged; Attitude of Health Personnel; Dyskinesia, Drug-Induced; Female; H | 2005 |
Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dysk | 2007 |
Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Data Interpretation, Statistical; De | 2007 |
Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial.
Topics: Adolescent; Alanine Transaminase; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior Dis | 2008 |
What CATIE found: results from the schizophrenia trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Dibenzothiaze | 2008 |
Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Dysk | 2008 |
Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Resistance; Dyskinesia, Drug-Induced; Female; Haloperid | 1994 |
Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Fe | 1995 |
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind M | 1993 |
Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Double-Blind Method; Drug The | 1996 |
A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial. ARCS Study Group. Assessment of Risperdal in a Clinical Setting.
Topics: Adult; Aged; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Patient Compliance; Psychi | 1997 |
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Female; | 1997 |
Risperidone in levodopa induced dyskinesiae.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Femal | 1998 |
A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Child; Dose- | 1999 |
A naturalistic study of risperidone maintenance treatment of outpatients with severe mental illness.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Chronic Disease; Drug Administration | 1999 |
Risperidone in treatment-refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Brief Psychiatric Rating Scale; Cholinergic Ant | 1999 |
Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depression; Depressive Disorder | 1999 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; | 2000 |
A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Chronic Disease; Delusions; Dyskinesia, Drug-I | 2000 |
Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dementia; Dementia, Vascular; Dose | 2000 |
Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; | 2002 |
Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness.
Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Autistic Disorder; Child; Dyskinesia, Drug-I | 2002 |
112 other studies available for risperidone and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Withdrawal-Emergent Dyskinesia After Acute Discontinuation of Risperidone in a Child With Autism Spectrum Disorder.
Topics: Antipsychotic Agents; Autism Spectrum Disorder; Child; Dyskinesia, Drug-Induced; Humans; Male; Rispe | 2018 |
Assessment of adverse effects of neurotropic drugs in monkeys with the "drug effects on the nervous system" (DENS) scale.
Topics: Algorithms; Animals; Antipsychotic Agents; Autonomic Nervous System; Basal Ganglia Diseases; Behavio | 2013 |
Clozapine-associated asterixis: case report.
Topics: Aged; Antipsychotic Agents; Clozapine; Drug Substitution; Drug Therapy, Combination; Dyskinesia, Dru | 2014 |
Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Dru | 2015 |
Neurological Adverse Effects of Antipsychotics in Children and Adolescents.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Drug-Related Side Effect | 2015 |
Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Cholinergi | 2016 |
Clinical experiences and clinical trials.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dyskinesia, Drug-Induced; Humans; Olanzapine | 2008 |
Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Topics: Adult; Alleles; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Genetic Markers; Genotype; H | 2008 |
Treatment of generalized tardive dystonia with clozapine.
Topics: Adult; Antipsychotic Agents; Clozapine; Dyskinesia, Drug-Induced; Dystonic Disorders; Follow-Up Stud | 2008 |
Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Belgium; Benzodiazepines; Brief Psychiatric Rat | 2009 |
Extrapyramidal side effects: could you identify them in the emergency department?
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Dopamine Antagonists; Dyskinesi | 2009 |
Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature.
Topics: Adult; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; | 2010 |
Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Asian People; Delayed-Action Pr | 2009 |
Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Administration Sch | 2009 |
Withdrawal-emergent respiratory dyskinesia with risperidone treated with clozapine.
Topics: Anti-Dyskinesia Agents; Antipsychotic Agents; Clozapine; Dyskinesia, Drug-Induced; Female; Humans; M | 2010 |
Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Dyskinesia, Drug-Ind | 2011 |
The emerging role of atypical antipsychotics in the treatment of tardive dyskinesia induced by other atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Brain; Drug Substitution; Dyskinesia, Drug-Induced; Humans; O | 2011 |
Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia.
Topics: Aged; Blood-Brain Barrier; Dementia; Domperidone; Dopamine Antagonists; Dopamine D2 Receptor Antagon | 2011 |
Atypical presentation of tardive dyskinesia associated with risperidone long-acting injection as maintenance treatment in bipolar affective disorder: a case report.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Delayed-Action Preparations; Drug Therapy, | 2012 |
Tardive dyskinesia with risperidone and anticholinergics.
Topics: Adult; Biperiden; Cholinergic Antagonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Fema | 2002 |
Use of atypical antipsychotics in a Veterans Affairs hospital.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Utilization; Dyskinesia, Drug-Induced; Female; Hospitals | 2002 |
Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relations | 2003 |
Haloperidol versus risperidone on rat "early onset" vacuous chewing.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dose-Respons | 2004 |
Tardive dyskinesia in an autistic patient treated with risperidone.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Dyskinesia, Drug-Induced; Humans; Male; Risperi | 2004 |
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual | 2004 |
Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Therapy, Combination; Dyskine | 2004 |
Tardive dyskinesia following brief exposure to risperidone--a case study.
Topics: Adult; Antipsychotic Agents; Brain; Dyskinesia, Drug-Induced; Humans; Male; Risperidone; Schizophren | 2004 |
Movement disorders and the treatment of schizophrenia.
Topics: Antipsychotic Agents; Brain; Catatonia; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Lo | 2004 |
Improvement in tardive dyskinesia with aripiprazole use.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Drug Interactions; Drug Therapy, Combination; | 2005 |
Rabbit syndrome induced by combined lithium and risperidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Drug Therapy, Combination; Dy | 2005 |
Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Cost Savings; Costs and Cost Analysis; | 2005 |
Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness.
Topics: Adult; Aged; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochro | 2005 |
Respiratory dyskinesia as discontinuation effect of risperidone.
Topics: Aged, 80 and over; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Respiratory Muscl | 2005 |
Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Longitudina | 2006 |
Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperid | 2006 |
Antipsychotic drugs and schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dyskinesia, Drug-Induced; Humans; Olanzap | 2006 |
New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Haloperidol; Humans; Inciden | 2006 |
Risperidone and late onset tics.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Dyskinesia, Drug-Induced; Female; Follow | 2006 |
Behavioural effects of chronic haloperidol and risperidone treatment in rats.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Disease Models, Animal; Dopamine Antagonists; | 2006 |
Obsessive compulsive disorder treatment in patients with Down syndrome: a case series.
Topics: Adult; Antipsychotic Agents; Down Syndrome; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle A | 2006 |
[Neurotoxicity related to lithium-risperidon combination treatment in a patient with schizoaffective disorder].
Topics: Antimanic Agents; Antipsychotic Agents; Cognition Disorders; Drug Interactions; Drug Therapy, Combin | 2007 |
Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia.
Topics: Adult; Aged; Anti-Dyskinesia Agents; Antipsychotic Agents; Chronic Disease; Dyskinesia, Drug-Induced | 2006 |
Pisa syndrome-like peculiar posture occurred while running was successfully improved with risperidone.
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Jogging; M | 2006 |
Oral candidiasis secondary to adverse anticholinergic effects of psychotropic medications.
Topics: Antipsychotic Agents; Benztropine; Candidiasis, Oral; Child; Drug Therapy, Combination; Dyskinesia, | 2007 |
Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Body Weight; Chlorpromazine; Clozapine; Dopamine; Dyskinesia, Drug-In | 2007 |
Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Drug Utilization; Dyskinesia, | 2007 |
Acute dyskinesia on starting methylphenidate after risperidone withdrawal.
Topics: Acute Disease; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2007 |
Atypical antipsychotic withdrawal dyskinesia in 4 patients with mood disorders.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Ag | 2007 |
Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delayed-Action Preparations; Dyski | 2007 |
Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam.
Topics: Aged; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Biperiden; Central Nervous Syst | 2007 |
Abnormal movements with the addition of clindamycin to risperidone in a girl with autism.
Topics: Adolescent; Anti-Bacterial Agents; Antipsychotic Agents; Autistic Disorder; Clindamycin; Drug Therap | 2008 |
Risperidone and obsessive-compulsive symptoms.
Topics: Antipsychotic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Administration Schedu | 1994 |
Schizophrenia and severe tardive dyskinesia responsive to risperidone.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Hal | 1994 |
Risperidone and tardive dyskinesia: a case report.
Topics: Adult; Antipsychotic Agents; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; | 1995 |
Cost-benefits of new drugs.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Dyskinesia, Drug-Induced; Humans; Risperidone; Schizoph | 1995 |
Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes.
Topics: Aged; Antiparkinson Agents; Clozapine; Dyskinesia, Drug-Induced; Humans; Male; Parkinson Disease; Pa | 1995 |
Risperidone-induced tardive dyskinesia.
Topics: Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; | 1996 |
Neuroleptic-induced tardive dyskinesia.
Topics: Adolescent; Basal Ganglia Diseases; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Fluoxetine; | 1996 |
Tardive dyskinesia induced by risperidone?
Topics: Adult; Drug Administration Schedule; Dyskinesia, Drug-Induced; Humans; Male; Risperidone; Schizophre | 1996 |
Severe depression with risperidone-induced EPS in an elderly schizoaffective patient.
Topics: Aged; Antipsychotic Agents; Depressive Disorder; Dose-Response Relationship, Drug; Dyskinesia, Drug- | 1996 |
Improvement of debilitating tardive dyskinesia with risperidone.
Topics: Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Risperidone | 1996 |
Risperidone and obsessive-compulsive symptoms.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Obsessive-Compulsive Disorder; Risk Factors; | 1996 |
Withdrawal-emergent dyskinesia in a patient on risperidone undergoing dosage reduction.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Male; Risperidone; Schizophrenia, Par | 1996 |
Risperidone and tardive dyskinesia.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Depressive Disorder | 1996 |
Risperidone-induced tardive dyskinesia and parkinsonism.
Topics: Aged; Antipsychotic Agents; Bipolar Disorder; Dyskinesia, Drug-Induced; Humans; Male; Neurologic Exa | 1997 |
Substituting traditional antipsychotics with risperidone for individuals with mental retardation.
Topics: Adult; Aged; Antipsychotic Agents; Comorbidity; Dose-Response Relationship, Drug; Dyskinesia, Drug-I | 1996 |
Tics with risperidone withdrawal.
Topics: Antipsychotic Agents; Child; Dyskinesia, Drug-Induced; Humans; Male; Risperidone; Substance Withdraw | 1997 |
The use of risperidone in severely demented patients with persistent vocalizations.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Dyskinesia, Drug-Induced; Female; Geriatric | 1997 |
Extrapyramidal side effects with low-dose risperidone.
Topics: Adult; Antipsychotic Agents; Delusions; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; | 1997 |
Risperidone in the treatment of psychosis and concomitant buccolinguomasticatory dyskinesia in the elderly.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Depressive Disorder; Dyskinesia, Drug-Induced; Female | 1997 |
TD from risperidone?
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Dyskinesia, Drug-In | 1997 |
Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults.
Topics: Adult; Aggression; Antipsychotic Agents; Comorbidity; Dose-Response Relationship, Drug; Drug Adminis | 1997 |
Tardive dyskinesia during treatment with risperidone.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Risperidone; Schizophrenia | 1997 |
Risperidone-induced tardive dyskinesia.
Topics: Antipsychotic Agents; Depressive Disorder; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induce | 1998 |
Extrapyramidal reactions from concurrent SSRI and atypical antipsychotic use.
Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsych | 1998 |
Risperidone-induced tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Male; Risperidone; Schizophrenia | 1998 |
Risperidone and tardive dyskinesia in organic psychosis.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Male; Risperidone | 1998 |
Managing antipsychotic-induced acute and tardive dystonia.
Topics: Antipsychotic Agents; Cholinergic Antagonists; Clozapine; Dyskinesia, Drug-Induced; Dystonia; Humans | 1998 |
Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Dy | 1998 |
Rapid onset tardive dyskinesia ("fly catcher tongue") in a neuroleptically naive patient induced by risperidone.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Dyskinesia, Drug-Induced; Hum | 1998 |
[Severe tardive dyskinesia during treatment with risperidone and fluoxetine].
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Fluoxetine; Humans | 1998 |
Progression of abnormal involuntary movements during risperidone treatment.
Topics: Adult; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Psychotic Disorders; Risperidone | 1998 |
Movement disorders in children with developmental disabilities taking risperidone.
Topics: Adolescent; Antipsychotic Agents; Child; Developmental Disabilities; Dyskinesia, Drug-Induced; Femal | 1999 |
Risperidone-induced rabbit syndrome: an unusual movement disorder caused by an atypical antipsychotic.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Male; Risperidone; Schizophrenia, Par | 1999 |
Risperidone-induced tardive dyskinesia in first-episode psychotic patients.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Male; Risperidone; Schizophrenia | 1999 |
Risperidone treatment of tardive dyskinesia and dystonia.
Topics: Antipsychotic Agents; Diazepam; Dopamine Antagonists; Drug Administration Schedule; Drug Therapy, Co | 1999 |
Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients.
Topics: Aged; Antipsychotic Agents; Chi-Square Distribution; Dyskinesia, Drug-Induced; Female; Haloperidol; | 1999 |
Tardive dystonia induced by risperidone.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Male; Risperidone; Schizophrenia | 1999 |
Risperidone-induced tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Risperidone; Schizophrenia | 1999 |
Chorea and tardive dyskinesia in a patient taking risperidone.
Topics: Adolescent; Aggression; Antipsychotic Agents; Chorea; Dyskinesia, Drug-Induced; Female; Humans; Ment | 1999 |
Tardive dyskinesia from risperidone and olanzapine in an alcoholic man.
Topics: Alcoholism; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 1; Dyskinesia, Drug-Induc | 1999 |
Attention deficit-hyperactivity disorder may be a risk factor for treatment-emergent tardive dyskinesia induced by risperidone.
Topics: Adult; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Dyskinesia, Drug-Induced | 2000 |
Tardive dyskinesia in older patients.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiaz | 2000 |
Tardive dyskinesia from low-dose risperidone.
Topics: Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Huma | 2000 |
Risperidone implicated in the onset of tardive dyskinesia in a young woman.
Topics: Adolescent; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Risperidone; Schizophren | 2000 |
[Atypical antipsychotics].
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; | 2000 |
Risperidone and withdrawal dyskinesia.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Dibenzothiazepines; | 2000 |
Risperidone-induced tardive dyskinesia.
Topics: Adult; Anti-Dyskinesia Agents; Antipsychotic Agents; Biperiden; Blepharospasm; Botulinum Toxins; Clo | 2000 |
Tardive dystonia provoked by concomitantly administered risperidone.
Topics: Adolescent; Antipsychotic Agents; Chlorpromazine; Drug Therapy, Combination; Dyskinesia, Drug-Induce | 2000 |
Risperidone and tardive dyskinesia: a case of blepharospasm.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blepharospasm; Dyskinesia, Drug-Induced; Humans; Male; | 2000 |
Improvement of tardive dyskinesia with risperidone: a case report.
Topics: Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Risperidone | 2000 |
Acute and long-term treatment of catatonia with risperidone.
Topics: Acute Disease; Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Long-Term Care; Male; | 2001 |
Risperidone and tardive dyskinesia.
Topics: Antipsychotic Agents; Data Interpretation, Statistical; Dyskinesia, Drug-Induced; Humans; Risk Asses | 2001 |
Olanzapine in the treatment of tardive dyskinesia: a report of 2 cases.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; | 2001 |
Tardive dyskinesia caused by the atypical antipsychotic risperidone and cured by the use of another drug of the same class, olanzapine.
Topics: Adult; Benzodiazepines; Dyskinesia, Drug-Induced; Humans; Male; Neurologic Examination; Olanzapine; | 2001 |
Risperidone, tardive dyskinesia, and the elderly.
Topics: Age Factors; Aged; Antipsychotic Agents; Dementia; Dyskinesia, Drug-Induced; Follow-Up Studies; Huma | 2001 |
Risperidone for tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Male; Risperidone; Severity of Illnes | 2001 |
Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson's disease.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Hepatolenticular Degeneratio | 2001 |
Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Depressive Disorder, Majo | 2001 |
Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing.
Topics: Amisulpride; Animals; Antipsychotic Agents; Clozapine; Dopamine; Dose-Response Relationship, Drug; D | 2002 |
Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Cell Cycle; Cell Survival; Clozapine; | 2001 |
Clinical profile of an atypical antipsychotic: risperidone.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Neurologic Examination; Psychiatric Status R | 2002 |